Individuals Coming Off Anti-Obesity Medications Gain Back Pounds at a Quadrupled Rate Compared to People Using Diet and Exercise

A recent study reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional diet and exercise plans.

Findings released in a major health publication demonstrates that while overweight people often shed about a fifth of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.

"Individuals using such drugs should be aware of the risk of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.

This pace of regain implies a reversion to original weight within about one and a half years.

Analyzing Treatments

The research, which reviewed dozens of studies involving thousands of participants, compared the results of the injectable medications with older methods.

The team emphasize that individuals who lose weight through dieting generally have a slower creep back—around 0.1 kg a month—post-intervention.

Explaining the Fast Regain

Nutrition scientists propose the way of the drugs is key to understanding the accelerated regain.

The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating much more probable."

A Lifelong Disease?

The NHS recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.

Professionals contend that, considering the high risk of weight regain, the treatment is often long-term.

This perspective is reinforced by pharmaceutical companies, who note that the findings "emphasize the long-term character of obesity," akin to managing diseases like hypertension.

User Accounts

Users who have stopped the medication explain a sudden resurgence of appetite.

"I experienced something that goes on and you become ravenous," described a patient.

This difficulty is compounded if users have not developed permanent dietary or behavioural changes during therapy.

Widespread Adoption

Survey data show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.

• Adoption is greater among women than males.
• The 40s and 50s age group shows the greatest level of interest.
• Many access the drugs through private prescriptions rather than public health services.

Ultimately, researchers stress that while these medications are powerful tools for shedding pounds, they are not a magic solution and long-term success hinges on ongoing lifestyle support.